In a large study of 400 people with HIV-related belly fat, tesamorelin reduced visceral fat by nearly 11% after 6 months, compared to less than 1% in the placebo group, and also reduced waist and trunk fat while increasing IGF-1 levels.

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.